OTCM
ITNS
Market cap609kUSD
Jul 24, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-80.95%
IPO
-99.76%
Name
ITonis Inc
Chart & Performance
P/E
—
P/S
338.35
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-27.70%
Revenues
2k
-40.95%
Net income
-38k
L+405.92%
CFO
-112k
L+1,248.28%
Profile
Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is headquartered in Laguna Hills, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||
Revenues | 2 -40.95% | 3 -31.10% | ||||||
Cost of revenue | 2 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | 2 | 780 | ||||||
NOPBT Margin | 100.00% | 25.57% | ||||||
Operating Taxes | (168) | (228) | ||||||
Tax Rate | ||||||||
NOPAT | 170 | 229 | ||||||
Net income | (38) 405.92% | (8) -89.39% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 74 | |||||||
BB yield | -12.06% | |||||||
| Debt | ||||||||
Debt current | 910 | 910 | ||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 910 | 910 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (112) | (8) | ||||||
CAPEX | ||||||||
Cash from investing activities | 2 | |||||||
Cash from financing activities | 112 | 4 | ||||||
FCF | 93 | 219 | ||||||
| Balance | ||||||||
Cash | 443 | 738 | ||||||
Long term investments | ||||||||
Excess cash | 353 | 586 | ||||||
Stockholders' equity | (16,206) | (16,168) | ||||||
Invested Capital | 16,062 | 15,947 | ||||||
ROIC | 1.06% | 1.44% | ||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,523,410 | 1,523,410 | ||||||
Price | 0.00 -33.33% | 0.00 -71.43% | ||||||
Market cap | 609 -33.33% | 914 -71.43% | ||||||
EV | 1,520 | 1,824 | ||||||
EBITDA | 2 | 780 | ||||||
EV/EBITDA | 843.90 | 2,338.78 | ||||||
Interest | ||||||||
Interest/NOPBT | ||||||||